4CXI

BTB domain of KEAP1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.255 
  • R-Value Work: 0.185 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Structure of the Btb Domain of Keap1 and its Interaction with the Triterpenoid Antagonist Cddo.

Cleasby, A.Yon, J.Day, P.J.Richardson, C.Tickle, I.J.Williams, P.A.Callahan, J.F.Carr, R.Concha, N.Kerns, J.K.Qi, H.Sweitzer, T.Ward, P.Davies, T.G.

(2014) Plos One 9: 98896

  • DOI: 10.1371/journal.pone.0098896
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The protein Keap1 is central to the regulation of the Nrf2-mediated cytoprotective response, and is increasingly recognized as an important target for therapeutic intervention in a range of diseases involving excessive oxidative stress and inflammati ...

    The protein Keap1 is central to the regulation of the Nrf2-mediated cytoprotective response, and is increasingly recognized as an important target for therapeutic intervention in a range of diseases involving excessive oxidative stress and inflammation. The BTB domain of Keap1 plays key roles in sensing environmental electrophiles and in mediating interactions with the Cul3/Rbx1 E3 ubiquitin ligase system, and is believed to be the target for several small molecule covalent activators of the Nrf2 pathway. However, despite structural information being available for several BTB domains from related proteins, there have been no reported crystal structures of Keap1 BTB, and this has precluded a detailed understanding of its mechanism of action and interaction with antagonists. We report here the first structure of the BTB domain of Keap1, which is thought to contain the key cysteine residue responsible for interaction with electrophiles, as well as structures of the covalent complex with the antagonist CDDO/bardoxolone, and of the constitutively inactive C151W BTB mutant. In addition to providing the first structural confirmation of antagonist binding to Keap1 BTB, we also present biochemical evidence that adduction of Cys 151 by CDDO is capable of inhibiting the binding of Cul3 to Keap1, and discuss how this class of compound might exert Nrf2 activation through disruption of the BTB-Cul3 interface.


    Organizational Affiliation

    GlaxoSmithKline, Collegeville, Pennsylvania, United States of America.,GlaxoSmithKline, Stevenage, United Kingdom.,GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America.,Astex Pharmaceuticals, Cambridge, United Kingdom.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
KELCH-LIKE ECH-ASSOCIATED PROTEIN 1
A
137Homo sapiensMutation(s): 1 
Gene Names: KEAP1 (INRF2, KIAA0132, KLHL19)
Find proteins for Q14145 (Homo sapiens)
Go to Gene View: KEAP1
Go to UniProtKB:  Q14145
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.255 
  • R-Value Work: 0.185 
  • Space Group: P 65 2 2
Unit Cell:
Length (Å)Angle (°)
a = 42.807α = 90.00
b = 42.807β = 90.00
c = 266.506γ = 120.00
Software Package:
Software NamePurpose
PHASERphasing
SCALAdata scaling
REFMACrefinement
XDSdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2014-06-18
    Type: Initial release